Plain English Summary
Background and study aims
1-2% of the UK population have heart failure, which accounts for around 900,000 people in the UK. The main aims of heart failure treatment include reducing symptoms, improving levels of activity, reducing the number of hospital visits and improving how patients feel (quality of life). This study is focused on a group of older people in the UK who have recently been started on a treatment with a drug called ivabradine for heart failure. This study aims to examine their quality of life over a period of time after starting the treatment.
Who can participate?
People aged at least 70 years, who have heart failure and who have been started on ivabradine medication for their heart failure by their doctor can participate in this study.
What does the study involve?
Patients will see their doctor as usual and complete two short questionnaires to assess their quality of life. Their doctor will record their heart rate and blood pressure, and conduct a walking test where applicable, on entry to the study, after two months and then again after four months. These tests and questions are carried out as part of normal care. Patients will be followed up for around 6 months.
What are the possible benefits and risks of participating?
There are no direct benefits expected from being involved in the research, although the results could be used to improve patient care in future. There are no additional risks of participating as usual clinical care continues throughout the study. The risks of personal data being disclosed are slight as only encrypted anonymised data will leave NHS premises.
Where is the study run from?
The study is run from about 50 UK sites (including general practices and hospital outpatient departments).
When is study starting and how long is it expected to run for?
The study will start in January 2014 and is expected to run until August 2014.
Who is funding the study?
The study is funded by Servier Laboratories Ltd (UK).
Who is the main contact?
Medical Information - Servier
LIVE:LIFE - OLder heart failure patients Initiated on iVabradinE in UK quaLIty of liFE
The hypothesis is that we will see an improvement in the quality of life, i.e. a greater than 20% reduction of the baseline Minnesota Living With Heart Failure Scores (lower scores meaning a better quality of life).
Submitted to UK NRES: North East Newcastle and North Tyneside 2, Reference 13/NE/0345
Multicentre longitudinal observational single-cohort study
Primary study design
Secondary study design
Quality of life
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Heart failure with left ventricular systolic dysfunction
This is an observational study so clinical care will continue as usual.
At baseline, at two months and at six months:
1. Heart rate, blood pressure and 6-minute walk test (where offered) will be recorded
2. Responses to the Minnesota Living With Heart Failure Questionnaire and SF12 questionaire will be used to formally assess quality of life
After a further 12 months (i.e. at 18 months from baseline) data about patients' medications (i.e. doses and total number) will be collected from their medical records.
Primary outcome measures
Change in total score from the Minnesota Living with Heart Failure Questionnaire at six months. The change from baseline will be evaluated using the paired t-test.
Secondary outcome measures
1. Change in 6-minute walking test data at six months is the key secondary outcome measure. The change from baseline will be evaluated using the paired t-test
2. The numbers of patients experiencing clinically significant changes (defined as a change of 5 units or more from baseline) in the Minnesota Living With Heart Failure Questionnaire will also be assessed
Overall trial start date
Overall trial end date
Participant inclusion criteria
Heart failure patients:
1. Aged 70 years or older
2. Where a decision has already been made to initiate ivabradine for treatment of HF as per licensed indication for heart failure, i.e.:
2.1. Chronic heart failure New York Heart Association (NYHA) Class II to IV with systolic dysfunction
2.1. In sinus rhythm with resting HR ≥75 beats per min
2.3. In combination with standard therapy including beta blockers or when beta blockers are contraindicated or not tolerated
3. Who have given their informed consent
Target number of participants
Participant exclusion criteria
1. Patients not receiving ivabradine as planned within 2 weeks from inclusion in the study
2. Patients no longer under the care of a study physician (named in the delegation log)
3. Patients enrolled or planning to be enrolled into an interventional clinical trial
4. Patients prescribed ivabradine in a manner not consistent with the Summary of Product Characteristics (SmPC) for congestive heart failure (CHF) with left ventricular systolic dysfunction (LVSD)
5. Patients with cognitive impairment to such a degree that the investigator feels they would be unable to complete the study
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Queen Alexandra Hospital
Servier Laboratories Ltd (UK)
Servier Laboratories Ltd. (UK)
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting